2 days ago
Dishman Carbogen shares in focus after Swiss subsidiary signs CHF 25 million co-investment agreement
Shares of Dishman Carbogen Amcis Ltd. could see increased investor interest after its Swiss subsidiary, CARBOGEN AMCIS AG, announced a strategic co-investment exceeding CHF 25 million with a key Japanese client. The deal is aimed at expanding antibody-drug conjugate (ADC) manufacturing capabilities at the company's Aarau and Neuland sites in Switzerland.
The investment will specifically support the production of a drug linker used in commercial ADCs, an area witnessing rising global demand. Under the agreement, both sites will undergo significant upgrades: Aarau will see the installation of 850-litre reactors and agitated filter dryers by Q1 2027, while similar enhancements at Neuland are scheduled for completion by Q3 2027.
This development marks the second major collaboration between CARBOGEN AMCIS and the same customer, building on a 2021 joint funding project for the Bubendorf site. The announcement reaffirms the company's growing importance in handling complex, high-potency APIs and delivering end-to-end CDMO (Contract Development and Manufacturing Organization) services across global markets.
Given the scale and strategic nature of this co-investment, the move is expected to bolster Dishman Carbogen's long-term growth outlook and may reflect positively in its stock performance in the coming sessions.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
